What is the half-life of Cangrelor?

Cangrelor has a half-life of approximately 2.6 minutes, which is notably short among antiplatelet agents. This rapid half-life allows for quick onset and offset of action, making Cangrelor particularly useful in situations where immediate antiplatelet effects are required, such as during percutaneous coronary interventions. The short duration of action means that the antiplatelet effects dissipate rapidly once the infusion is stopped, providing flexibility in managing the patient's bleeding risk in cases where it might become necessary to halt antiplatelet therapy. This pharmacokinetic profile is distinct and advantageous compared to other antiplatelet drugs with longer half-lives, which can lead to prolonged effects and increased bleeding risk even after cessation of the drug.